JP2014530237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530237A5 JP2014530237A5 JP2014535867A JP2014535867A JP2014530237A5 JP 2014530237 A5 JP2014530237 A5 JP 2014530237A5 JP 2014535867 A JP2014535867 A JP 2014535867A JP 2014535867 A JP2014535867 A JP 2014535867A JP 2014530237 A5 JP2014530237 A5 JP 2014530237A5
- Authority
- JP
- Japan
- Prior art keywords
- benzothiazol
- dihydroisoquinolin
- ylcarbamoyl
- carboxylic acid
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)C(*C(NC)=O)=O Chemical compound CC(C)C(*C(NC)=O)=O 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547165P | 2011-10-14 | 2011-10-14 | |
| US61/547,165 | 2011-10-14 | ||
| CNPCT/CN2012/078372 | 2012-07-09 | ||
| CN2012078372 | 2012-07-09 | ||
| PCT/US2012/059717 WO2013055895A1 (en) | 2011-10-14 | 2012-10-11 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016226799A Division JP6337068B2 (ja) | 2011-10-14 | 2016-11-22 | 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530237A JP2014530237A (ja) | 2014-11-17 |
| JP2014530237A5 true JP2014530237A5 (en:Method) | 2015-12-03 |
| JP6049738B2 JP6049738B2 (ja) | 2016-12-21 |
Family
ID=47073545
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535867A Expired - Fee Related JP6049738B2 (ja) | 2011-10-14 | 2012-10-11 | 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤 |
| JP2016226799A Expired - Fee Related JP6337068B2 (ja) | 2011-10-14 | 2016-11-22 | 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016226799A Expired - Fee Related JP6337068B2 (ja) | 2011-10-14 | 2016-11-22 | 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤 |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP2768830B1 (en:Method) |
| JP (2) | JP6049738B2 (en:Method) |
| KR (1) | KR102056587B1 (en:Method) |
| CN (1) | CN109535155B (en:Method) |
| AR (1) | AR088328A1 (en:Method) |
| AU (2) | AU2012322818A1 (en:Method) |
| BR (1) | BR112014009052B1 (en:Method) |
| CA (1) | CA2850976C (en:Method) |
| CL (1) | CL2014000922A1 (en:Method) |
| CO (1) | CO6950477A2 (en:Method) |
| DO (1) | DOP2014000074A (en:Method) |
| EC (1) | ECSP14000606A (en:Method) |
| ES (1) | ES2699966T3 (en:Method) |
| IL (1) | IL231926A (en:Method) |
| MX (2) | MX364950B (en:Method) |
| PE (2) | PE20141997A1 (en:Method) |
| PH (1) | PH12014500815B1 (en:Method) |
| RU (1) | RU2594282C2 (en:Method) |
| SG (2) | SG10201606031XA (en:Method) |
| TW (1) | TWI561521B (en:Method) |
| UY (1) | UY34381A (en:Method) |
| WO (1) | WO2013055895A1 (en:Method) |
| ZA (1) | ZA201402555B (en:Method) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| AU2015360621A1 (en) * | 2014-12-09 | 2017-06-29 | Abbvie Inc. | Bcl-xL inhibitory compounds and antibody drug conjugates including the same |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| CN114173772A (zh) * | 2019-04-12 | 2022-03-11 | 托尼克斯医药控股公司 | Cd40-cd154结合的抑制剂 |
| KR102316961B1 (ko) * | 2020-01-29 | 2021-10-26 | 프라비바이오 주식회사 | 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물 |
| EP4251209A1 (en) | 2020-11-24 | 2023-10-04 | Novartis AG | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CN117794929A (zh) | 2021-02-02 | 2024-03-29 | 法国施维雅药厂 | 选择性bcl-xl protac化合物及使用方法 |
| EP4525925A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CA3256012A1 (en) | 2022-05-20 | 2023-11-23 | Les Laboratoires Servier | ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| WO1997010223A1 (en) | 1995-09-15 | 1997-03-20 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone n-oxides |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| ES2294494T3 (es) | 2004-04-19 | 2008-04-01 | Symed Labs Limited | Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados. |
| KR101389246B1 (ko) * | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
| US7297700B2 (en) * | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| ES2525229T3 (es) | 2007-02-15 | 2014-12-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolinas como ligandos de TAAR1 |
| CA2686545C (en) | 2007-04-19 | 2010-11-02 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090137457A1 (en) | 2007-10-02 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| US8410124B2 (en) | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| NZ593537A (en) * | 2008-12-19 | 2013-07-26 | Genentech Inc | Isoquinoline derivatives and methods of use |
| ES2462715T3 (es) * | 2008-12-19 | 2014-05-26 | Genentech, Inc. | Compuestos y métodos de uso |
| KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| TWI571466B (zh) | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
-
2012
- 2012-10-08 TW TW101137132A patent/TWI561521B/zh not_active IP Right Cessation
- 2012-10-10 UY UY0001034381A patent/UY34381A/es unknown
- 2012-10-11 BR BR112014009052-1A patent/BR112014009052B1/pt not_active IP Right Cessation
- 2012-10-11 CA CA2850976A patent/CA2850976C/en active Active
- 2012-10-11 PE PE2014000520A patent/PE20141997A1/es active IP Right Grant
- 2012-10-11 PE PE2018001273A patent/PE20181357A1/es unknown
- 2012-10-11 AU AU2012322818A patent/AU2012322818A1/en not_active Abandoned
- 2012-10-11 PH PH1/2014/500815A patent/PH12014500815B1/en unknown
- 2012-10-11 SG SG10201606031XA patent/SG10201606031XA/en unknown
- 2012-10-11 ES ES12778012T patent/ES2699966T3/es active Active
- 2012-10-11 WO PCT/US2012/059717 patent/WO2013055895A1/en not_active Ceased
- 2012-10-11 CN CN201910042347.5A patent/CN109535155B/zh not_active Expired - Fee Related
- 2012-10-11 JP JP2014535867A patent/JP6049738B2/ja not_active Expired - Fee Related
- 2012-10-11 MX MX2017014059A patent/MX364950B/es unknown
- 2012-10-11 SG SG11201401479SA patent/SG11201401479SA/en unknown
- 2012-10-11 EP EP12778012.0A patent/EP2768830B1/en active Active
- 2012-10-11 RU RU2014119254/04A patent/RU2594282C2/ru active
- 2012-10-11 EP EP17185702.2A patent/EP3266776A1/en not_active Withdrawn
- 2012-10-11 MX MX2014004561A patent/MX351970B/es active IP Right Grant
- 2012-10-11 KR KR1020147012847A patent/KR102056587B1/ko not_active Expired - Fee Related
- 2012-10-12 AR ARP120103812A patent/AR088328A1/es not_active Application Discontinuation
-
2014
- 2014-04-03 IL IL231926A patent/IL231926A/en active IP Right Grant
- 2014-04-08 ZA ZA201402555A patent/ZA201402555B/en unknown
- 2014-04-11 DO DO2014000074A patent/DOP2014000074A/es unknown
- 2014-04-11 CL CL2014000922A patent/CL2014000922A1/es unknown
- 2014-05-07 CO CO14097119A patent/CO6950477A2/es unknown
- 2014-05-13 EC ECIEPI2014606A patent/ECSP14000606A/es unknown
-
2016
- 2016-11-22 JP JP2016226799A patent/JP6337068B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-17 AU AU2017206149A patent/AU2017206149B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530237A5 (en:Method) | ||
| RU2014119254A (ru) | Средства, вызывающие апоптоз, для лечения злокачественных новообразований и иммунных и аутоиммунных заболеваний | |
| JP2014530238A5 (en:Method) | ||
| DK2609091T3 (en) | Pharmaceutically active compounds as AXL inhibitors | |
| US8815926B2 (en) | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases | |
| JP2020503299A5 (en:Method) | ||
| JP2020531498A5 (en:Method) | ||
| CN112204027A (zh) | Erk 抑制剂及其应用 | |
| JP2021501220A5 (en:Method) | ||
| AU2013365926A1 (en) | Novel heterocyclic compounds as bromodomain inhibitors | |
| JP2012528178A5 (en:Method) | ||
| HRP20160539T1 (hr) | Antagonisti trpv4 | |
| HRP20130106T1 (hr) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
| RU2014119250A (ru) | Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2010513304A5 (en:Method) | ||
| JP2018510857A5 (en:Method) | ||
| JP2016525076A5 (en:Method) | ||
| HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
| JP2012532931A5 (en:Method) | ||
| US20220388964A1 (en) | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions | |
| US20130317024A1 (en) | Pyrrolopyrrolidinone compounds | |
| JP2016538313A5 (en:Method) | ||
| JP2010528995A5 (en:Method) | ||
| JP2019523233A5 (en:Method) | ||
| IL259424A (en) | History of indole converted to nitrogen as pge2 receptor modulators |